Ingmar Gorman is a US-based licensed psychologist and co-founder of Fluence, a training company in psychedelic-assisted therapy. He has served as site co-principal investigator on an FDA-approved Phase 3 clinical trial of MDMA-assisted psychotherapy for PTSD and as a study therapist in clinical trials of psilocybin for treatment-resistant depression. His work focuses on psychedelic harm reduction and integration. He has co-authored a peer-reviewed article featured on the ICEERS website calling for evidence-based psychedelic integration.
